Tag Archives: Eli Lilly

ImaginAB’s Minibodies for CD8+ T Cell Targeting – Select Optimal Immunotherapy Approaches

ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading →

EGFR Antibody Necitumumab Recommended for Lung Cancer & Other Anti-EGFR MAb’s to Address EGFR Resistance

The Oncology Drug Advisory Committee voted (informally) to recommend approval of Lilly’s necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). Continue reading →

Pin It on Pinterest